Literature DB >> 14978510

A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor.

Roselyne Tournaire1, Marie-Pierre Simon, Ferdinand le Noble, Anne Eichmann, Patrick England, Jacques Pouysségur.   

Abstract

Tie2, an endothelial cell-specific receptor kinase, has an important role in tumour angiogenesis. In an attempt to identify peptides that specifically interact with and block the Tie2 pathway, a phage-displayed peptide library was screened on a recombinant Tie2 receptor. One peptide, NLLMAAS, completely abolished the binding to Tie2 of both angiopoietin 2 and angiopoietin 1 (Ang1). We further show that NLLMAAS specifically suppresses both Ang1-induced ERK activity and migration in human umbilical endothelial cells. Moreover, in vivo, this peptide inhibits angiogenesis in the chick chorioallantoic membrane assay. NLLMAAS is the first peptide described to interact with Tie2. Our results demonstrate that it is an efficient and specific antagonist of the binding of Tie2 ligands, and suggest that this peptide or its derivates may have potential applications in the treatment of angiogenesis diseases. It also represents a potent tool to dissect the molecular mechanisms involved in the Tie2 pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978510      PMCID: PMC1299011          DOI: 10.1038/sj.embor.7400100

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  29 in total

1.  Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice.

Authors:  W S Shim; M Teh; P O Mack; R Ge
Journal:  Int J Cancer       Date:  2001-10-01       Impact factor: 7.396

2.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation.

Authors:  T N Sato; Y Tozawa; U Deutsch; K Wolburg-Buchholz; Y Fujiwara; M Gendron-Maguire; T Gridley; H Wolburg; W Risau; Y Qin
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

3.  Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.

Authors:  S E Cwirla; P Balasubramanian; D J Duffin; C R Wagstrom; C M Gates; S C Singer; A M Davis; R L Tansik; L C Mattheakis; C M Boytos; P J Schatz; D P Baccanari; N C Wrighton; R W Barrett; W J Dower
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

4.  Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.

Authors:  A Stratmann; T Acker; A M Burger; K Amann; W Risau; K H Plate
Journal:  Int J Cancer       Date:  2001-02-01       Impact factor: 7.396

5.  EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells.

Authors:  Injune Kim; Young Shin Ryu; Hee Jin Kwak; So Young Ahn; Jong-Lark Oh; George D Yancopoulos; Nicholas W Gale; Gou Young Koh
Journal:  FASEB J       Date:  2002-05-21       Impact factor: 5.191

6.  Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.

Authors:  S Davis; T H Aldrich; P F Jones; A Acheson; D L Compton; V Jain; T E Ryan; J Bruno; C Radziejewski; P C Maisonpierre; G D Yancopoulos
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

7.  A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth.

Authors:  Xiyun Yan; Yun Lin; Dongling Yang; Yi Shen; Mei Yuan; Zhiqiang Zhang; Peiyu Li; Hongtian Xia; Li Li; Dandan Luo; Qin Liu; Karlheinz Mann; Bernhard L Bader
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

8.  Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.

Authors:  A Papapetropoulos; G García-Cardeña; T J Dengler; P C Maisonpierre; G D Yancopoulos; W C Sessa
Journal:  Lab Invest       Date:  1999-02       Impact factor: 5.662

9.  Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2.

Authors:  Rebekah R White; Siqing Shan; Christopher P Rusconi; Geetha Shetty; Mark W Dewhirst; Christopher D Kontos; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-11       Impact factor: 11.205

10.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis.

Authors:  A Stratmann; W Risau; K H Plate
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

View more
  29 in total

1.  Tie1 deficiency induces endothelial-mesenchymal transition.

Authors:  Julie Garcia; Maria José Sandi; Pierre Cordelier; Bernard Binétruy; Jacques Pouysségur; Juan Lucio Iovanna; Roselyne Tournaire
Journal:  EMBO Rep       Date:  2012-05-01       Impact factor: 8.807

2.  The angiopoietin-Tie2 signaling axis in the vascular leakage of systemic inflammation.

Authors:  Katelyn E Milam; Samir M Parikh
Journal:  Tissue Barriers       Date:  2015-04-03

3.  A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.

Authors:  G M Palmer; Z Tiran; Z Zhou; M E Capozzi; W Park; C Coletta; A Pyriochou; Y Kliger; O Levy; I Borukhov; M W Dewhirst; G Rotman; J S Penn; A Papapetropoulos
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality.

Authors:  Sascha David; Chandra C Ghosh; Philipp Kümpers; Nelli Shushakova; Paul Van Slyke; Eliyahu V Khankin; S Ananth Karumanchi; Dan Dumont; Samir M Parikh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-03-18       Impact factor: 5.464

5.  HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model.

Authors:  Tong-Young Lee; Judah Folkman; Kashi Javaherian
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

Review 6.  Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes.

Authors:  A M Isidori; M A Venneri; D Fiore
Journal:  J Endocrinol Invest       Date:  2016-06-25       Impact factor: 4.256

7.  A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells.

Authors:  Zheng-Fang Yi; Sung-Gook Cho; Hui Zhao; Yuan-Yuan Wu; Jian Luo; Dali Li; Tingfang Yi; Xun Xu; Zirong Wu; Mingyao Liu
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

8.  Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation.

Authors:  Sung-Gook Cho; Zhengfang Yi; Xiufeng Pang; Tingfang Yi; Ying Wang; Jian Luo; Zirong Wu; Dali Li; Mingyao Liu
Journal:  Cancer Res       Date:  2009-08-11       Impact factor: 12.701

9.  Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3.

Authors:  Srinivas Reddy Boreddy; Ravi P Sahu; Sanjay K Srivastava
Journal:  PLoS One       Date:  2011-10-10       Impact factor: 3.240

10.  TNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma.

Authors:  Marjorie Adjuto-Saccone; Philippe Soubeyran; Julie Garcia; Stéphane Audebert; Luc Camoin; Marion Rubis; Julie Roques; Bernard Binétruy; Juan Lucio Iovanna; Roselyne Tournaire
Journal:  Cell Death Dis       Date:  2021-06-25       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.